- Markets
- Healthcare
- RAYLA
RAYLA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Raymed Labs do?
Raymed Labs Ltd specializes in the manufacturing of a diverse range of pharmaceutical products including antibiotics, anti-inflammatories, and other medications for both human and veterinary use.
Who are the competitors of Raymed Labs?
Raymed Labs major competitors are Hemo Organic, Zyden Gentec, Fabino Enterprises, Shamrock Indl. Co, Ganga Pharma., MPS Pharmaa, Adline Chem Lab. Market Cap of Raymed Labs is ₹1 Crs. While the median market cap of its peers are ₹6 Crs.
Is Raymed Labs financially stable compared to its competitors?
Raymed Labs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Raymed Labs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Raymed Labs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Raymed Labs allocated its funds?
NA
How strong is Raymed Labs balance sheet?
Raymed Labs balance sheet is weak and might have solvency issues
Is the profitablity of Raymed Labs improving?
The profit is oscillating. The profit of Raymed Labs is -₹0.1 Crs for Mar 2024, -₹0.17 Crs for Mar 2023 and -₹0.08 Crs for Mar 2022
Is the debt of Raymed Labs increasing or decreasing?
Yes, The debt of Raymed Labs is increasing. Latest debt of Raymed Labs is ₹2.71 Crs as of Dec-24. This is greater than Mar-24 when it was ₹0 Crs.
Is Raymed Labs stock expensive?
Raymed Labs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Raymed Labs is 0.0, while 3 year average PE is -0.01. Also latest EV/EBITDA of Raymed Labs is 0.0 while 3yr average is 107.
Has the share price of Raymed Labs grown faster than its competition?
Raymed Labs has given better returns compared to its competitors. Raymed Labs has grown at ~26.12% over the last 3yrs while peers have grown at a median rate of 9.64%
Is the promoter bullish about Raymed Labs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Raymed Labs is 28.36% and last quarter promoter holding is 28.36%.
Are mutual funds buying/selling Raymed Labs?
There is Insufficient data to gauge this.